Research & KnowledgeEvent: September 1, 2026
AstraZeneca is advancing epithelial science to better understand what drives inflammatory diseases, including eosinophilic esophagitis (EoE)
Published
Signal category
Research & Knowledge
Quote
“how our teams at AstraZeneca are advancing epithelial science to better understand what drives inflammatory diseases, such as eosinophilic esophagitis (EoE)”
— Suffwan Eltom|AstraZeneca team
Company
- Industry
- Pharmaceutical Manufacturing
- Location
- Cambridge, GB
- Company size
- 82,045 employees
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio